|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6.09B 5.63B 5.25B 9.85B 659B 9.95B 66.93B 26B 323B 26.13B 25.56B 1,124B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.93B 5.48B 5.11B 9.59B 641B 9.68B 65.13B 25.3B 315B 25.43B 24.87B 1,094B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| 6 months | +0.26% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 37.76 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 23/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/2025 |
| Chief Tech/Sci/R&D Officer | - | 30/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01-06 | Issuer sale | Director | 17,475 | 0.0689% | ||
| 01-06 | Issuer sale | Director | 41,100 | 0.1621% | ||
| 01-06 | Issuer sale | Director | 42,920 | 0.1693% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 55.92M 51.68M 48.24M 90.45M 6.05B 91.33M 615M 239M 2.97B 240M 235M 10.33B | 1.28M 1.12M 1.03M 962K 1.8M 121M 1.82M 12.26M 4.76M 59.23M 4.79M 4.68M 206M |
| Net income | -22.93M -20.07M -18.54M -17.31M -32.46M -2.17B -32.77M -221M -85.68M -1.07B -86.09M -84.22M -3.7B | -170M -149M -137M -128M -240M -16.08B -243M -1.63B -635M -7.89B -638M -624M -27.44B |
| Net Debt | -30.9M -27.04M -24.99M -23.32M -43.74M -2.93B -44.16M -297M -115M -1.44B -116M -113M -4.99B | -186M -163M -151M -141M -264M -17.63B -266M -1.79B -696M -8.65B -699M -684M -30.09B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
